AbbVie has denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker was in advanced discussions to acquire the cancer-drug developer, citing people familiar with the matter. The company “is not in discussions with Revolution Medicines,” AbbVie said in an emailed statement to Reuters. The report did not include a deal value, but the biotech has a market value of over $15.4 billion as of the stock’s last close.
Read the full article: AbbVie Denies Media Reports of Talks to Buy Revolution Medicines //
Source: https://finance.yahoo.com/news/abbvie-talks-buy-biotech-revolution-200059398.html